Jeremy Grimshaw

Dr. Jeremy M. Grimshaw, MBChB, PhD, FRCGP, FCAHS is a Canadian health information specialist and epidemiologist based in Ottawa, Ontario.

Grimshaw is a Tier 1 Canada Research Chair in Health Knowledge Transfer and Uptake.¹⁾

• Faculty of Medicine, University of Edinburgh, 1979 - 1984
• Faculty of Medicine, University of Aberdeen, 1989 - 1997

Grimshaw is a fellow of the Canadian Academy of Health Sciences.²⁾

Grimshaw is a professor in the Department of Medicine at the University of Ottawa.³⁾

Grimshaw is the President of the Board of the Directors of the Campbell Collaboration.⁴⁾

He was initially elected as co-chair in 2016.⁵⁾

Grimshaw is a Senior Scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute.⁶⁾

Grimshaw sits on the board of directors at the Eastern Ontario Regional Laboratory Association.⁷⁾

Grimshaw has been a presenter for AcademyHealth.⁸⁾

Grimshaw is a member of the Behavioural Science Working Group of the Ontario COVID-19 Science Advisory Table.⁹⁾

Grimshaw received a strategic grant from the Cardiac Arrhythmia Network of Canada for a study titled “Decreasing Hospital Admissions from the Emergency Department for Acute Atrial Fibrillation”.¹⁰⁾ CANC is partnered with many organizations with interest in COVID-19 including Apotex, Bayer, Boehringer Ingelheim, IBM, Johnson & Johnson, LifeLabs, Medtronic, Pfizer, and St. Jude Medical (an Abbott company).¹¹⁾

Grimshaw is a co-Principal Investigator and co-Chair of the COVID-END study, funded by the Canadian Institutes of Health Research (CIHR).¹²⁾ He is also a member of the Canadian secretariat.¹³⁾

Grimshaw is a co-founder of the Behavioural, Environmental, Social and System Interventions Collaboration (BESSI), “which aims to promote research into BESSIs to reduce transmission and mitigate the effects of the pandemic.”¹⁴⁾

Grimshaw is a co-investigator for the Coronavirus Variants Rapid Response Network (CoVaRR-Net), funded by the Canadian Institutes of Health Research (CIHR).¹⁵⁾

Grimshaw received funding from the Public Health Agency of Canada (PHAC) for a study on vaccine hesitancy related to COVID-19 vaccines.¹⁶⁾

Grimshaw received an operating grant from as a co-Principal Investigator from Diabetes Action Canada for a study called “An implementation science approach to increase attendance to retinopathy screening by people with diabetes.”¹⁷⁾ DAC is funded by AstraZeneca, Bayer, Merck and Sun Life Financial.¹⁸⁾

Grimshaw has published research on antimicrobial resistance with funding by the Joint Programming Initiative on Antimicrobial Resistance Network (JPIARN).¹⁹⁾

Grimshaw was recognized as a Thomson Reuters Highly Cited Researcher in 2015, 2016 2017 and 2018.^{20) 21)}